pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-628 |
Genomic Coordinates | chr15: 55372940 - 55373034 |
Synonyms | MIRN628, hsa-mir-628, MIR628 |
Description | Homo sapiens miR-628 stem-loop |
Comment | The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies . |
RNA Secondary Structure | ![]() |
Associated Diseases | ![]() |
Mature miRNA Information | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-628-3p | ||||||||||||||||||||||||||||
Sequence | 61| UCUAGUAAGAGUGGCAGUCGA |81 | ||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||
Experiments | Microarray | ||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
DRVs in miRNA |
|
||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | FBXO21 | ||||||||||||||||||||
Synonyms | FBX21 | ||||||||||||||||||||
Description | F-box protein 21 | ||||||||||||||||||||
Transcript | NM_015002 | ||||||||||||||||||||
Other Transcripts | NM_033624 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on FBXO21 | |||||||||||||||||||||
3'UTR of FBXO21 (miRNA target sites are highlighted) |
>FBXO21|NM_015002|3'UTR 1 AGTCTAGAGAGGACATTGCACCTTTGCTGCTGCTGCTATCTTCCAAGAGAACGGGACTCCGGAAGAAGACGTCTCCACGG 81 AGCCCTCGGGACCTGCTGCACCAGGAAAGCCACTCCACCAGTAGTGCTGGTTGCCTCCTACTAAGTTTAAATACCGTGTG 161 CTCTTCCCCAGCTGCAAAGACAATGTTGCTCTCCGCCTACACTAGTGAATTAATCTGAAAGGCACTGTGTCAGTGGCATG 241 GCTTGTATGCTTGTCCTGTGGTGACAGTTTGTGACATTCTGTCTTCATGAGGTCTCACAGTCGACGCTCCTGTAATCATT 321 CTTTGTATTCACTCCATTCCCCTGTCTGTCTGCATTTGTCTCAGAACATTTCCTTGGCTGGACAGATGGGGTTATGCATT 401 TGCAATAATTTCCTTCTGATTTCTCTGTGGAACGTGTTCGGTCCCGAGTGAGGACTGTGTGTCTTTTTACCCTGAAGTTA 481 GTTGCATATTCAGAGGTAAAGTTGTGTGCTATCTTGGCAGCATCTTAGAGATGGAGACATTAACAAGCTAATGGTAATTA 561 GAATCATTTGAATTTATTTTTTTCTAATATGTGAAACACAGATTTCAAGTGTTTTATCTTTTTTTTTTAAATTTAAATGG 641 GAATATAACACAGTTTTCCCTTCCATATTCCTCTCTTGAGTTTATGCACATCTCTATAAATCATTAGTTTTCTATTTTAT 721 TACATAAAATTCTTTTAGAAAATGCAAATAGTGAACTTTGTGAATGGATTTTTCCATACTCATCTACAATTCCTCCATTT 801 TAAATGACTACTTTTATTTTTTAATTTAAAAAATCTACTTCAGTATCATGAGTAGGTCTTACATCAGTGATGGGTTCTTT 881 TTGTAGTGAGACATACAAATCTGATGTTAATGTTTGCTCTTAGAAGTCATACTCCATGGTCTTCAAAGACCAAAAAATGA 961 GGTTTTGCTTTTGTAATCAGGAAAAAAAAAAATTAATGAACCTTAAAAAAAAAAAAAAAGGTTTTGAAGGGAAAAAAAGT 1041 GGTTTCACACCTCTTGTTATTCCTTAGAGTCACTTCAAGGCCTGTTTGAATGTGGCAGGTTAGAAAGAGAGAGAATGTCT 1121 TTCATTTGAAGAGTGTTGGACTTGTGTGAAAGGAGATGTGCGTGTTGGAATCTGCTTTTCCAAGCCGCCAGGGTCCTGAC 1201 GGCAGCAGGACGAAGCCTGTTGTGGCGTCTTCTGGGAAAGCCTGACCGTGTGTTCGGACGGCACTGGCTCCTTTCCGAAG 1281 TTCTCAGTAACTGAGCCCAGAGTAACTGCACGCCTTTGTGCAGCTCTGGAGCTCCACCAACTCTCGGCCTGCCAGTTCTC 1361 AAGCGAGCTAATCTTGTCATTAATCGATAGAAGCTAACTTCCGAAGTTAGGACCTAGTTACTTTGCTCTCAACATTTAAA 1441 ATAATGCAGTTGCTCTAGTGAATGGGGCGTTAGGGGCCTGTCTCTGCACCTGTCTGTCCATCTGCATGCAGTATTCTCAC 1521 CCATGTTGAATGCCTGCTGCTTGTTTACCCTTTGGAAACCCTGGGGTGACCAAGGTTTGGAAAGCCACCTGAGACCACTT 1601 CATAGCAAGGGAAGGCTTTAAGCAGTTACTAGAAAGAGATGGGGATTTGGCCCCTGGCTCCTCCAGCCTGAATGAGCTAT 1681 TTAATCCACTGTCCATGTTCCTCATCAGTCAAATCCAAAGTCAAAGGATTTGAACCTGCATCTGGAAACGTAACCACTCA 1761 CAGCACCTGGCCCGCCAAGGTTGGGAGGATTGTACACTACTTTCATTTAAAGGGGAAAGTTTGATAATACGGAATTAATT 1841 AATATGAATGAGATGCATTAATAAGAACCTGAGCATGCTGAGAGTTGCAATTGTTGGTTTTCTGGTTTGATTGATTTCCT 1921 TTTTTCTTAGACACATCAAAGTCAAGAAAGATGGTTTTACCTTTACTGACCCAGCTGTACATATGTATCTAGACTGTTTT 2001 TAAATGTCTTTCTTCATGAATGCTTCATGGGGCTCCAGGAAGCCTGTATCACCTGTGTAAGTTGGTATTTGGGCACTTTA 2081 TATTTTTCTAAAAACGTGTTTTGGATCCTGTACTCTAATAAATCATAAGTTTCTTTTTAAAAATTTTCCAAAACTTTTCT 2161 CCATTTTAAAAAGCCCTGTTATAAACGTTGAACTTTCACAATGTTAAAATGTTAAATATTTGGATATAGCAACTTCTTTT 2241 CTCTTCAAATGAATGCCAAGATTTTTTTGTACAATGATTAATAAATGGAACTTATCCAGAGAAACCAAAAAAAAAAAAAA 2321 AA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293S |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM1084065. RNA binding protein: AGO2. Condition:CLIP_emetine_AbnovaAb
... - Karginov FV; Hannon GJ, 2013, Genes & development. |
Article |
- Karginov FV; Hannon GJ - Genes & development, 2013
When adapting to environmental stress, cells attenuate and reprogram their translational output. In part, these altered translation profiles are established through changes in the interactions between RNA-binding proteins and mRNAs. The Argonaute 2 (Ago2)/microRNA (miRNA) machinery has been shown to participate in stress-induced translational up-regulation of a particular mRNA, CAT-1; however, a detailed, transcriptome-wide understanding of the involvement of Ago2 in the process has been lacking. Here, we profiled the overall changes in Ago2-mRNA interactions upon arsenite stress by cross-linking immunoprecipitation (CLIP) followed by high-throughput sequencing (CLIP-seq). Ago2 displayed a significant remodeling of its transcript occupancy, with the majority of 3' untranslated region (UTR) and coding sequence (CDS) sites exhibiting stronger interaction. Interestingly, target sites that were destined for release from Ago2 upon stress were depleted in miRNA complementarity signatures, suggesting an alternative mode of interaction. To compare the changes in Ago2-binding patterns across transcripts with changes in their translational states, we measured mRNA profiles on ribosome/polysome gradients by RNA sequencing (RNA-seq). Increased Ago2 occupancy correlated with stronger repression of translation for those mRNAs, as evidenced by a shift toward lighter gradient fractions upon stress, while release of Ago2 was associated with the limited number of transcripts that remained translated. Taken together, these data point to a role for Ago2 and the mammalian miRNAs in mediating the translational component of the stress response.
LinkOut: [PMID: 23824327]
|
CLIP-seq Support 1 for dataset GSM1084065 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_emetine_AbnovaAb |
Location of target site | ENST00000427718.2 | 3UTR | GAAAGAGAUGGGGAUUU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
27 hsa-miR-628-3p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT039584 | CDC14A | cell division cycle 14A | ![]() |
1 | 1 | |||||||
MIRT039585 | AGO1 | argonaute 1, RISC catalytic component | ![]() |
![]() |
2 | 3 | ||||||
MIRT039586 | TGFBRAP1 | transforming growth factor beta receptor associated protein 1 | ![]() |
1 | 1 | |||||||
MIRT039587 | LRP6 | LDL receptor related protein 6 | ![]() |
1 | 1 | |||||||
MIRT071876 | BTF3L4 | basic transcription factor 3 like 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT097443 | JMY | junction mediating and regulatory protein, p53 cofactor | ![]() |
![]() |
2 | 4 | ||||||
MIRT100100 | ABT1 | activator of basal transcription 1 | ![]() |
![]() |
2 | 8 | ||||||
MIRT147692 | CBX4 | chromobox 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT408248 | PURA | purine rich element binding protein A | ![]() |
![]() |
2 | 2 | ||||||
MIRT442047 | LRAT | lecithin retinol acyltransferase | ![]() |
![]() |
2 | 2 | ||||||
MIRT444412 | RAB3IP | RAB3A interacting protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT452599 | REPIN1 | replication initiator 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT469515 | RBFOX2 | RNA binding protein, fox-1 homolog 2 | ![]() |
![]() |
2 | 8 | ||||||
MIRT498192 | AKR1B10 | aldo-keto reductase family 1 member B10 | ![]() |
![]() |
2 | 2 | ||||||
MIRT500151 | CREBBP | CREB binding protein | ![]() |
![]() |
2 | 2 | ||||||
MIRT507319 | FAM60A | SIN3-HDAC complex associated factor | ![]() |
![]() |
2 | 6 | ||||||
MIRT508343 | ZNF273 | zinc finger protein 273 | ![]() |
![]() |
2 | 6 | ||||||
MIRT520480 | TRIM13 | tripartite motif containing 13 | ![]() |
![]() |
2 | 2 | ||||||
MIRT522461 | MMP16 | matrix metallopeptidase 16 | ![]() |
![]() |
2 | 4 | ||||||
MIRT547116 | PHLPP2 | PH domain and leucine rich repeat protein phosphatase 2 | ![]() |
![]() |
2 | 2 | ||||||
MIRT548675 | CRNKL1 | crooked neck pre-mRNA splicing factor 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT553756 | TARBP2 | TARBP2, RISC loading complex RNA binding subunit | ![]() |
![]() |
2 | 4 | ||||||
MIRT559437 | ARSJ | arylsulfatase family member J | ![]() |
![]() |
2 | 2 | ||||||
MIRT610490 | GPC4 | glypican 4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT644682 | TMCO1 | transmembrane and coiled-coil domains 1 | ![]() |
![]() |
2 | 2 | ||||||
MIRT658214 | FBXO21 | F-box protein 21 | ![]() |
![]() |
2 | 2 | ||||||
MIRT756083 | TP53 | tumor protein p53 | 4 | 1 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|